PMID: 8941008Dec 1, 1996Paper

Pharmacoeconomic profile of paclitaxel as a first-line treatment for patients with advanced ovarian carcinoma. A lifetime cost-effectiveness analysis

Cancer
A MessoriE Tendi

Abstract

Analysis of published survival curves has recently been proposed as a method for conducting incremental cost-effectiveness analysis in which two treatments are compared with each other in terms of cost per year of life gained. In patients with advanced ovarian carcinoma, the combination of paclitaxel and cisplatin has been reported to improve survival more significantly than standard therapy with cyclophosphamide and cisplatin. However, the high cost of paclitaxel indicates a need for an evaluation of the pharmacoeconomic profile of these treatments. The authors conducted an incremental cost-effectiveness analysis to assess the paclitaxel-based regimen in terms of cost per year of life gained. The analysis utilized data from a published controlled long term trial involving 184 patients treated with paclitaxel and cisplatin and 202 patients treated with cyclophosphamide and cisplatin. Gompertz' law was employed to obtain the lifetime estimate of the years gained by patients given the first treatment in comparison with patients given the second. The paclitaxel-based treatment was found to improve life expectancy by 46 years for every 100 patients. Costs of chemotherapy were higher in the paclitaxel group than in the standard-ther...Continue Reading

References

Mar 31, 1977·The New England Journal of Medicine·M C Weinstein, W B Stason
Oct 1, 1992·AJR. American Journal of Roentgenology·J J CaroM McGregor
Aug 1, 1981·Journal of Pharmacokinetics and Biopharmaceutics·L B Sheiner, S L Beal
Jul 1, 1995·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·F RecchiaL Frati
Apr 1, 1995·Digestive Diseases and Sciences·A MessoriN Martini
Mar 16, 1994·Journal of the National Cancer Institute·M L BrownL M Shibley
Sep 25, 1993·BMJ : British Medical Journal·R Robinson
Feb 1, 1996·The New England Journal of Medicine·A N Schechter, G P Rodgers
Feb 1, 1996·The New England Journal of Medicine·A D Forman
Mar 28, 1996·The New England Journal of Medicine·M A Testa, D C Simonson
May 2, 1996·The New England Journal of Medicine·P A UbelD A Asch
May 9, 1996·The New England Journal of Medicine·J W Gamel, M J Edwards
Dec 1, 1996·Journal of Clinical Gastroenterology·A MessoriE Tendi

❮ Previous
Next ❯

Citations

Feb 24, 2001·The New England Journal of Medicine·M VaianiA Messori
Jun 1, 2005·Expert Review of Pharmacoeconomics & Outcomes Research·Konstantin J DedesThomas D Szucs
Aug 25, 2015·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Matteo RuggeriAmerico Cicchetti
May 13, 2014·Journal of the American College of Cardiology·Andrea MessoriSabrina Trippoli
Jan 19, 2018·Therapeutic Advances in Medical Oncology·Andrea MessoriMaria Claudia D'Avella
Aug 18, 2000·PharmacoEconomics·D Bodurka-BeversD M Gershenson

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.